Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Sales and Divestitures (2023 - 2025)

Ocular Therapeutix has reported Gains from Sales and Divestitures over the past 4 years, most recently at $1.6 million for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 21.47% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 21.47%, while the annual FY2025 figure was $1.6 million, 21.47% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $1.6 million at Ocular Therapeutix, up from $1.3 million in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $1.6 million in Q4 2025 and troughed at $393805.0 in Q4 2023.
  • A 3-year average of $1.1 million and a median of $1.3 million in 2024 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 224.37% in 2024 and later rose 21.47% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $393805.0 in 2023, then soared by 224.37% to $1.3 million in 2024, then increased by 21.47% to $1.6 million in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for OCUL at $1.6 million in Q4 2025, $1.3 million in Q4 2024, and $393805.0 in Q4 2023.